A novel spectroscopically determined pharmacodynamic biomarker for skin toxicity in cancer patients treated with targeted agents

Cancer Research

Volumn 77, Issue 2, 2017, Pages 557-565

  Azan, Antoine ^a   Caspers, Peter J ^b,c   Bakker Schut, Tom C ^b,c   Roy, Séverine ^d   Boutros, Céline ^d   Mateus, Christine ^d   Routier, Emilie ^d   Besse, Benjamin ^d   Planchard, David ^d   Seck, Atmane ^d   Kom, Nyam Kamsu ^e   Tomasic, Gorana ^d   Koljenović, Senada ^b   Hegt, Vincent Noordhoek ^b   Texier, Matthieu ^f   Lanoy, Emilie ^f   Eggermont, Alexander M M ^d,g   Paci, Angelo ^a,d   Robert, Caroline ^d,e,g   Puppels, Gerwin J ^b,c   Mir, Lluis M ^a   more..

^a CNRS   (France)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RIVERD INTERNATIONAL B V   (Netherlands)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e Universite Paris Sud   (France)

^f CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; B RAF KINASE INHIBITOR; BIOLOGICAL MARKER; DABRAFENIB; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ABSENCE OF SIDE EFFECTS; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; FOLLICULITIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INFLAMMATION; INSTRUMENT VALIDATION; KERATOSIS; NORMAL HUMAN; PARTIAL LEAST SQUARES REGRESSION; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; RAMAN SPECTROMETRY; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; SKIN BIOPSY; SKIN DISEASE; SKIN TOXICITY; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS; XERODERMA; AGED; ALGORITHM; AREA UNDER THE CURVE; CHEMISTRY; CLINICAL TRIAL; DRUG ERUPTIONS; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; SKIN;

AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOMARKERS; DRUG ERUPTIONS; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MIDDLE AGED; OXIMES; PILOT PROJECTS; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SKIN; SPECTRUM ANALYSIS, RAMAN; SULFONAMIDES;

EID: 85018160921     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-1733     Document Type: Article

References (49)

1. Platz A, Egyhazi S, Ringborg U, Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008;1:395-405.
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
3. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002;25:511-8.
4. Ballantyne AD, Garnock-Jones KP. Dabrafenib: first global approval. Drugs 2013;73:1367-76.
5. Wright CJM, McCormack PL. Trametinib: first global approval. Drugs 2013;73:1245-54.
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
7. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011;8:426-33.
8. Kim G, McKee AE, Ning Y-M, Hazarika M, Theoret M, Johnson JR, et al. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res 2014;20:4994-5000.
9. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42.
10. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
11. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2014;372:141116004513004.
12. Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013;18:314-22.
13. Livingstone E, Zimmer L, Vaubel J, Schadendorf D. BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. Chin Clin Oncol 2014;3:29.
14. Manousaridis I, Mavridou S, Goerdt S, Leverkus M, Utikal J. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. J Eur Acad Dermatology Venereol 2013;27:11-8.
15. Robert C, Thomas M, Mateus C. MAP-kinase pathway up or down? Just look at the skin of your patients! Melanoma Res 2014;24:421-3.
16. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013;24:1691-7.
17. Notingher I.Raman spectroscopy cell-based biosensors. Sensors 2007;7:1343-58.
18. Downes A, Elfick A. Raman spectroscopy and related techniques in biomedicine. Sensors 2010;10:1871-89.
19. Haka AS, Volynskaya Z, Gardecki JA, Nazemi J, Lyons J, Hicks D, et al. In vivo margin assessment during partial mastectomy breast surgery using Raman spectroscopy. Cancer Res 2006;66:3317-22.
20. Barman I, Dingari NC, Saha A, McGee S, Galindo LH, Liu W, et al. Application of Raman spectroscopy to identify microcalcifications and underlying breast lesions at stereotactic core needle biopsy. Cancer Res 2013;73:3206-15.
21. Barroso EM, Smits RWH, Bakker Schut TC, ten Hove I, Hardillo JA, Wolvius EB, et al. Discrimination between oral cancer and healthy tissue based on water content determined by Raman spectroscopy. Anal Chem 2015;87:2419-26.
22. Downes A. Raman microscopy and associated techniques for label-free imaging of cancer tissue. Appl Spectrosc Rev 2015;50:641-53.
23. Ali SM, Bonnier F, Tfayli A, Lambkin H, Flynn K, McDonagh V, et al. Raman spectroscopic analysis of human skin tissue sections ex vivo: evaluation of the effects of tissue processing and dewaxing. J Biomed Opt 2013;18:61202.
24. Vyumvuhore R, Tfayli A, Piot O, Le Guillou M, Guichard N, Manfait M, et al. Raman spectroscopy: in vivo quick response code of skin physiological status. J Biomed Opt 2014;19:111603.
25. Puppels GJ, Sterrenborg HJC. Laser safety aspects of the use of the Model 3510 Skin Composition Analyzer (SCA) in in vivo studies of human subjects; 2007.
26. Sandby-Møller J, Poulsen T, Wulf HC. Epidermal thickness at different body sites: relationship to age, gender, pigmentation, blood content, skin type and smoking habits. Acta Derm Venereol 2003;83:410-3.
27. Caspers PJ, Lucassen GW, Puppels GJ. Combined invivo confocal Raman spectroscopy and confocal microscopy of human skin. Biophys J 2003;85:572-80.
28. Egawa M, Hirao T, Takahashi M. In vivo estimation of stratum corneum thickness from water concentration profiles obtained with Raman spectroscopy. Acta Derm Venereol 2007;87:4-8.
29. Caspers PJ, Lucassen GW, Carter EA, Bruining HA, Puppels GJ. In vivo confocal Raman microspectroscopy of the skin: noninvasive determination of molecular concentration profiles. J Invest Dermatol 2001;116:434-42.
30. Martens H, Stark E. Extended multiplicative signal correction and spectral interference subtraction: new preprocessing methods for near infrared spectroscopy. J Pharm Biomed Anal 1991;9:625-35.
31. Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics. Chemom Intell Lab Syst 2001;58:109-30.
32. Altman EI. Financial ratios, discriminant analysis and the prediction of corporate bankruptcy. J Finance 1968;23:589-609.
33. Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. Int Jt Conf Artif Intell 1995;2:1137-43.
34. Dunn OJ. Multiple comparisons among means. J Am Stat Assoc 1961;56:52-64.
35. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
36. Youden WJ.Index for rating diagnostic tests. Cancer 1950;3:32-5.
37. Lacouture ME, Anadkat MJ, Bensadoun R-J, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011;19:1079-95.
38. Balagula Y, Huston KB, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011;29:1114-21.
39. Mandalà M, Massi D, De Giorgi V. Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action. Crit Rev Oncol Hematol 2013;88:318-37.
40. Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013;14:e11-8.
41. Zhang C, Spevak W, Zhang Y, Burton EA, Ma Y, Habets G, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature 2015;526:583-6.
42. Belum VR, Fischer A, Choi JN, Lacouture ME. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep 2013;15:249-59.
43. Petit VW, Réfrégiers M, Guettier C, Jamme F, Sebanayakam K, Brunelle A, et al. Multimodal spectroscopy combining time-of-flight-secondary ion mass spectrometry, synchrotron-FT-IR, and synchrotron-UV microspectroscopies on the same tissue section. Anal Chem 2010;82:3963-8.
44. Santos IP, Caspers PJ, Schut TCB, van Doorn R, Hegt VN, Koljenovic S, et al. Raman spectroscopic characterization of melanoma and benign melanocytic lesions suspected of melanoma using High-wavenumber Raman Spectroscopy. Anal Chem 2016;88:7683-8.
45. Lui H, Zhao J, McLean D, Zeng H. Real-time Raman spectroscopy for in vivo skin cancer diagnosis. Cancer Res 2012;72:2491-500.
46. Lacouture ME.Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-12.
47. Hobbs RM, Silva-Vargas V, Groves R, Watt FM. Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions. J Invest Dermatol 2004;123:503-15.
48. Liu H, Wu Y, Lv T, Yao Y, Xiao Y, Yuan D, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2013;8:e55128.
49. Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012;78:8-15.